Valneva (NASDAQ:VALN) Reaches New 12-Month Low – What’s Next?

Shares of Valneva SE Sponsored ADR (NASDAQ:VALN) reached a new 52-week low during trading on Monday . The stock traded as low as $5.04 and last traded at $5.3330, with a volume of 27494 shares traded. The stock had previously closed at $5.19.

Analysts Set New Price Targets

Several research analysts have weighed in on the stock. Guggenheim set a $11.00 price objective on shares of Valneva in a research note on Thursday, April 16th. Wall Street Zen raised shares of Valneva from a “strong sell” rating to a “sell” rating in a research note on Monday, June 1st. Weiss Ratings restated a “sell (e+)” rating on shares of Valneva in a report on Thursday, June 18th. Finally, The Goldman Sachs Group downgraded shares of Valneva from a “neutral” rating to a “sell” rating and set a $4.90 price target on the stock. in a research note on Wednesday, April 22nd. Three analysts have rated the stock with a Buy rating and two have issued a Sell rating to the company’s stock. According to MarketBeat, Valneva currently has an average rating of “Hold” and a consensus price target of $11.97.

Valneva Price Performance

The stock has a market capitalization of $496.27 million, a price-to-earnings ratio of -2.80 and a beta of 1.75. The stock’s 50 day simple moving average is $5.60 and its 200-day simple moving average is $7.82. The company has a debt-to-equity ratio of 2.14, a current ratio of 2.14 and a quick ratio of 1.60.

Valneva (NASDAQ:VALN) last released its quarterly earnings data on Tuesday, March 31st. The company reported ($0.42) earnings per share (EPS) for the quarter. The business had revenue of $35.77 million during the quarter. Valneva had a negative net margin of 88.87% and a negative return on equity of 107.63%. On average, analysts expect that Valneva SE Sponsored ADR will post -1 EPS for the current fiscal year.

Hedge Funds Weigh In On Valneva

Institutional investors and hedge funds have recently bought and sold shares of the stock. Marex Group plc acquired a new position in Valneva during the 2nd quarter valued at $64,000. XTX Topco Ltd bought a new position in shares of Valneva during the 4th quarter worth about $94,000. JPMorgan Chase & Co. acquired a new position in shares of Valneva during the third quarter valued at about $124,000. VSM Wealth Advisory LLC raised its position in shares of Valneva by 125.0% during the third quarter. VSM Wealth Advisory LLC now owns 9,000 shares of the company’s stock valued at $110,000 after buying an additional 5,000 shares during the last quarter. Finally, China Universal Asset Management Co. Ltd. bought a new stake in shares of Valneva in the fourth quarter valued at about $44,000. Institutional investors own 11.39% of the company’s stock.

About Valneva

Valneva SE is a specialty vaccine company focused on the development and commercialization of prophylactic vaccines for infectious diseases. Headquartered in Saint-Herblain, France, the company applies inactivated whole-cell and recombinant technology platforms to address public health needs. Valneva’s research and development efforts span a range of viral and bacterial pathogens, with an emphasis on travel-related and emerging infectious diseases.

Among its marketed products, Valneva offers IXIARO®/JESPECT® for the prevention of Japanese encephalitis and DUKORAL® for the prevention of cholera and diarrhea caused by enterotoxigenic Escherichia coli.